1. Scrip
  2. >>Business

ReCode Combines With TranscripTx, Raises $80m For Novel RNA Drugs

 
• By Mandy Jackson

ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.

Molecule of DNA forming inside the test tube equipment.3d rendering,conceptual image.
ReCode's LNP platform can deliver RNA therapeutics and other genetic medicines • Source: Shutterstock

ReCode Therapeutics and TranscripTx have combined their development of RNA-based medicines under one banner, emerging under the ReCode banner with $80m in series A venture capital to complete preclinical studies and begin clinical trials for two therapeutics candidates designed to treat genetic respiratory diseases. ReCode Therapeutics also will use its new funding to advance its lipid nanoparticle (LNP) platform for organ-specific delivery of RNA therapies and other genetic medicines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.